Skip to content Skip to main menu Skip to utility menu

Drug safety notice: Pancreatic enzyme replacement therapy (PERT)

May 31, 2024

There is currently a shortage of the following medications:

Problem:

  • Creon 10,000 and 25,000 gastro-resistant capsules are in limited supply until 2 January 2026.
  • Nutrizym 22 capsules are out of stock until 16 August 2024.
  • Pancrex V capsules and powder remain available but are unable to support an increase in demand.
  • PERT is indicated for the treatment of pancreatic exocrine insufficiency such as in cystic fibrosis, pancreatic cancer, and pancreatitis.
  • There is no clinical alternative to PERT.
  • Unlicensed imports of Creon® capsules and alternative brands of PERT may be sourced, lead times vary.

Advice/alternative:

Clinicians and prescribers should review all patients prescribed PERT and:

  • Prescribe a maximum of one month’s supply at a time to help ensure there is sufficient stock for all patients.
  • Prioritise Creon 10,000 for paediatric patients and patients unable to take Creon 25,000 e.g. patients with swallowing difficulties.

For more information and further advice visit Drug Safety Notice or visit the National Patient Safety Alert document here.

If you have any questions please contact the pharmacy department on ext. 5263/3783.